威尔药业上半年净利7276.69万元，同比下降7.77%

Core Viewpoint - 威尔药业 reported a decline in both revenue and net profit for the first half of 2025, indicating challenges in the market and competitive pressures [1] Financial Performance - The company achieved a revenue of 674 million yuan, a year-on-year decrease of 2.1% [1] - The net profit attributable to shareholders was 72.77 million yuan, down 7.77% year-on-year [1] Product Performance - Sales volume of pharmaceutical excipients increased by 8.42% year-on-year, while sales revenue decreased by 5.97% [1] - The company focused on its advantageous products, with some excipients and raw materials seeing increased sales in the domestic market [1] Market Conditions - The domestic market is experiencing intensified competition, prompting the company to implement targeted marketing strategies [1] - The demand for traditional Chinese medicine injections has decreased year-on-year, leading to a reduction in sales of related injectable excipients [1] Supply Chain Impact - The influence of centralized drug procurement on drug prices is affecting upstream suppliers, including the company, which plays a crucial role in the supply chain [1] - The pricing of excipients is being impacted as a result of these market dynamics [1]